Overview

Dose-ranging Study to Assess the Efficacy and Safety of Ciclesonide HFA Nasal Aerosol in Adult and Adolescent Patients 12 Years and Older With Seasonal Allergic Rhinitis (SAR) (BY9010/M1-602)

Status:
Completed

Trial end date:
2007-07-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to demonstrate the efficacy of ciclesonide HFA, applied as a nasal aerosol once daily, in patients with SAR. The secondary objectives are to evaluate Quality-of-Life and safety.

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca

Treatments:

Ciclesonide